IRIS
BERARDI, Rossana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.108
EU - Europa 13.331
AS - Asia 11.704
SA - Sud America 2.844
AF - Africa 712
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 19
Totale 55.737
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.648
RU - Federazione Russa 4.099
SG - Singapore 3.870
VN - Vietnam 2.456
BR - Brasile 2.244
CN - Cina 1.842
IT - Italia 1.770
UA - Ucraina 1.357
HK - Hong Kong 1.259
DE - Germania 1.179
IE - Irlanda 1.078
SE - Svezia 845
FR - Francia 715
FI - Finlandia 661
TR - Turchia 583
GB - Regno Unito 514
DK - Danimarca 457
IN - India 386
CI - Costa d'Avorio 305
KR - Corea 268
CA - Canada 239
AR - Argentina 228
BD - Bangladesh 202
NL - Olanda 147
MX - Messico 141
PL - Polonia 134
JP - Giappone 129
ZA - Sudafrica 123
MA - Marocco 115
IQ - Iraq 109
ID - Indonesia 107
EC - Ecuador 99
CO - Colombia 83
PK - Pakistan 78
BE - Belgio 67
ES - Italia 63
AT - Austria 62
UZ - Uzbekistan 54
PH - Filippine 49
CL - Cile 46
VE - Venezuela 46
PY - Paraguay 38
KE - Kenya 32
SA - Arabia Saudita 31
TN - Tunisia 31
AZ - Azerbaigian 30
RO - Romania 30
EG - Egitto 28
MY - Malesia 28
PE - Perù 28
JO - Giordania 26
DZ - Algeria 25
LT - Lituania 24
KZ - Kazakistan 23
AE - Emirati Arabi Uniti 22
NP - Nepal 19
UY - Uruguay 19
CR - Costa Rica 17
CZ - Repubblica Ceca 17
TH - Thailandia 17
JM - Giamaica 14
TW - Taiwan 14
EU - Europa 13
IL - Israele 13
AL - Albania 12
AU - Australia 12
KG - Kirghizistan 12
CH - Svizzera 11
HN - Honduras 11
PS - Palestinian Territory 10
RS - Serbia 10
BG - Bulgaria 9
BH - Bahrain 9
BO - Bolivia 9
BY - Bielorussia 9
ET - Etiopia 9
LB - Libano 9
SK - Slovacchia (Repubblica Slovacca) 9
DO - Repubblica Dominicana 8
GR - Grecia 8
SN - Senegal 8
NG - Nigeria 7
NZ - Nuova Zelanda 7
BA - Bosnia-Erzegovina 6
HR - Croazia 6
KW - Kuwait 6
OM - Oman 6
PR - Porto Rico 6
PT - Portogallo 6
CY - Cipro 5
GE - Georgia 5
NI - Nicaragua 5
PA - Panama 5
SI - Slovenia 5
XK - ???statistics.table.value.countryCode.XK??? 5
AM - Armenia 4
AO - Angola 4
BW - Botswana 4
IR - Iran 4
LY - Libia 4
Totale 55.661
Salva come PNG Salva come JPEG
Città #
Ashburn 4.431
Dallas 2.558
Singapore 2.553
Chandler 2.048
Jacksonville 1.508
Fairfield 1.487
San Jose 1.301
Hong Kong 1.219
Des Moines 1.180
Dublin 1.069
Boardman 994
Ho Chi Minh City 782
Wilmington 732
New York 673
Woodbridge 660
Seattle 647
Houston 611
Hanoi 567
The Dalles 523
Ann Arbor 494
Cambridge 480
Beijing 451
Los Angeles 443
Lauterbourg 416
Lawrence 388
Princeton 388
Munich 367
San Mateo 364
Moscow 343
Abidjan 305
Helsinki 288
Hefei 231
Centro 217
São Paulo 208
San Diego 184
Buffalo 164
Chicago 154
Santa Clara 151
London 141
Turku 137
Da Nang 132
Orem 121
Warsaw 119
Ancona 118
Council Bluffs 118
Haiphong 117
Turin 117
Rome 113
Pune 106
Washington 102
Tokyo 101
Milan 84
Chennai 81
Rio de Janeiro 78
Montreal 76
Johannesburg 71
Guangzhou 70
Frankfurt am Main 69
Brussels 65
Denver 62
Shanghai 61
Nuremberg 60
Brooklyn 59
Atlanta 58
Vancouver 55
Poplar 53
Belo Horizonte 50
Columbus 49
Hải Dương 49
Stockholm 47
Tashkent 46
Mexico City 43
Amsterdam 42
Phoenix 42
Baghdad 41
Manchester 41
Marche 41
Boston 40
Falls Church 40
Biên Hòa 39
Brasília 37
Elk Grove Village 37
Norwalk 37
Salt Lake City 36
Curitiba 34
San Francisco 34
Dhaka 33
Quito 33
Wuhan 33
Mumbai 32
Porto Alegre 32
Urbisaglia 31
Thái Nguyên 29
Ankara 28
Nairobi 28
Baku 27
Guayaquil 27
Ninh Bình 27
Tolentino 27
Vienna 27
Totale 35.362
Salva come PNG Salva come JPEG
Nome #
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 2.280
Contrasting Digital Fake News in Health: an Interdisciplinary Approach 823
Contrasting Fake News in Oncology: The First Declaration of Good Communication 811
The Role of Hyponatraemia Before Surgery in Patients With Radical Resected Pancreatic Cancer 280
A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy 272
Metabolic phenotype of bladder cancer 251
Endometriosis-associated Clear Cell Carcinoma of the Abdominal Wall After Caesarean Section: A Case Report and Review of the Literature 235
Anemia may influence the outcome of patients undergoing neoadjuvant treatment for rectal cancer 214
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 213
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. 201
Impact of polypharmacy for chronic ailments in colon cancer patients: A review focused on drug repurposing. 201
Are liver nested stromal epithelial tumors always low aggressive? 199
Clinical impact of different exosomes’ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy 199
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy 194
The role of Aspirin as antitumoral agent for heavily pre-treated metastatic colorectal cancer patients receiving capecitabine monotherapy. BMC Cancer 194
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 191
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 190
1621P miRNA signature as early predictor of hyponatremia and survival in lung cancer: Preliminary results from the ISA retrospective study 190
Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach 187
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature 186
A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay 186
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 183
The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases 183
Optimal management of resected gastric cancer 181
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. 179
Modifications of taste sensitivity in cancer patients: a method for the evaluations of dysgeusia 179
Syndrome of inappropriate antidiuretic hormone secretion (Siadh): Optimal management 179
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 176
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors 176
85P NSCLC-Pro ClustAI: A machine learning model to prognostically stratify patients with advanced NSCLC treated with immune checkpoint inhibitors 175
A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. 173
Developments in the management of advanced soft-tissue sarcoma –€“ Olaratumab in context 171
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 170
Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO) 169
Long‑responders to anti‑HER2 therapies: A case report and review of the literature 168
5-Fluorouracil pharmacogenomics: still rocking after all these years? 167
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 166
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 166
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 166
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 165
A cost-benefit analysis of chemotherapy for gastric cancer. 165
Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 Pandemic 165
The role of an immune checkpoint score in resected non-small cell lung cancer patients' prognosis 164
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 163
Role of DCE-MR in predicting breast cancer subtypes. 163
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 162
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study 162
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab 162
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer 162
Nuclear factor-κB predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy. 161
Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going? 159
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy 159
Gender Differences and Outcomes in Melanoma Patients 158
Electrolyte disorders in cancer patients: a systematic review 158
Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. 157
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer 156
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 156
Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data 155
Adjuvant treatment after surgical resection 154
Squamous cell carcinoma of the lung: clinical criteria for treatment strategy 153
Medical treatment for cholangiocarcinoma 153
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 152
Managing hyponatremia in lung cancer: latest evidence and clinical implications 151
Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant Chemotherapy 150
Seminoma Retroperitoneal Relapse 23 Years After Surgery 150
High CTLA-4 expression correlates with poor prognosis in thymoma patients 149
Hyponatremia is a Predictor of Clinical Outcome for Resected Biliary Tract Cancers: A Retrospective Single-Center Study 149
The impact of lifestyle interventions in high‐risk early breast cancer patients: A modeling approach from a single institution experience 149
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 148
Lynphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. 148
Benefits and limitations of a multidisciplinary approach in cancer patient management 148
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis 147
Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival 146
Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review 145
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients 145
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review 144
Systemic treatment for lung carcinoids: from bench to bedside 144
Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. 143
Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients 143
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment 143
The role of angiogenetic single-nucleotide polymorphisms in thymic malignancies and thymic benign lesions 142
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials 142
A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial 141
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer 141
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer 141
Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer 141
Randomized active-controlled phase 2 study of Denosumab efficacy and safety in patients with breast cancer-related bone metastases. 140
Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms 140
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 140
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 140
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. 139
Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma 139
New target therapies in advanced pancreatic cancer. 138
Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. 138
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 138
Hyponatremia in cancer patients: Time for a new approach 138
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC 138
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 137
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 137
Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. 137
Totale 19.917
Salva come PNG Salva come JPEG
Categoria #
all - tutte 241.857
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 241.857
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021911 0 0 0 0 0 0 0 0 0 0 568 343
2021/20223.052 169 639 78 98 42 224 124 209 303 207 328 631
2022/20236.355 518 648 404 531 338 1.618 2 325 1.357 58 411 145
2023/20243.659 580 83 234 408 574 877 52 132 10 131 51 527
2024/20258.278 851 754 371 158 339 357 692 323 1.948 658 824 1.003
2025/202624.969 1.508 1.944 2.531 2.583 2.424 1.579 4.136 2.244 3.946 1.974 100 0
Totale 56.763